Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Hydrogel Urothelial Cancer Therapies
10
Mins
June 2025
Urological cancers are malignancies that affect the organs of the urinary system and male reproductive system. Of these, bladder cancer…
Read more
10
Mins
12 Jun 2025
Hydrogel Urothelial Cancer Therapies
Urological cancers are malignancies that affect the organs of the urinary system and male reproductive system. Of these, bladder cancer…
8
Mins
9 Jun 2025
How Targeted Approaches Are Transforming Management of Advanced EGFR-Mutant Lung Cancer
Overcoming Resistance: How Targeted Approaches Are Changing Management of Advanced EGFR-Mutant Lung Cancer and Pavingthe Way for Precision…
7
Mins
30 May 2025
Advances in 2L ER+/HER2− mBC therapy
Despite advances in first-line endocrine therapy (ET) plus cyclin-dependent 4/6 kinase inhibitors (CDK4/6i) in oestrogen receptor-positive…
7
Mins
23 May 2025
Inside the Cancer Vaccine Revolution: Interview with Lennard Lee
I’m a clinical academic, which is quite a rare breed of doctor, because what I’m doing, along with other clinical academics, is being…
15
Mins
31 Mar 2025
Endometrial Cancer Research in 2024
Endometrial cancer is one of the most common gynaecological cancers in high-income countries and, for many years, has been associated…
31 Oct 2024
Tackling Infectious Diseases
This interactive article summarises key discussions from GSK sponsored symposia that took place during the ESCMID Global Congress 2024, held from 27–30th April 2024 in Barcelona, Spain.
10
Mins
29 Oct 2024
ER+/HER2- Metastatic Breast Cancer – Treatment after ET + CDK4/6i
Over 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is ET.1-3 Advanced breast cancer (aBC) can be considered to…
8
Mins
29 Oct 2024
Patient-Centred Therapies for mNSCLC
The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of…
Loading posts...
1
2
3
…
29
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View